Physician profile
Sarah Mitchum
NPI 1356807507
$3,257.36
in general payments reported to CMS, 2019-2025
45 companies · $941 in 2025
The $941 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $193 · 2023: $1,043 · 2024: $1,080 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.01 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $602.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $320.49 | 2024-2025 | Veozah |
| Noven Therapeutics, LLC | $205.03 | 2023-2024 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.75 | 2022-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $167.09 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $146.38 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $115.97 | 2023-2025 | Gemtesa, Myfembree |
| Abbvie INC. | $115.34 | 2022-2025 | |
| Amgen INC. | $113.52 | 2023-2025 | Repatha, Evenity, Otezla |
| Otsuka America Pharmaceutical, INC. | $107.67 | 2023 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $105.83 | 2022-2025 | Farxiga, Airsupra |
| Shield Therapeutics INC | $89.51 | 2024-2025 | |
| Glaxosmithkline, LLC. | $70.67 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $67.08 | 2023-2024 | Spravato, Xarelto |
| Ardelyx, INC. | $55.63 | 2024-2025 | Ibsrela |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mitchum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.